BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析

◆英語タイトル:BioMarin Pharmaceutical Inc (BMRN) - Financial and Strategic SWOT Analysis Review
◆商品コード:SWOT20MY1647
◆発行会社(調査会社):GlobalData
◆発行日:2020年4月
◆ページ数:60
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:Pharmaceuticals and Healthcare
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD125 ⇒換算¥17,500見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD250 ⇒換算¥35,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD375 ⇒換算¥52,500見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

BioMarin Pharmaceutical Inc (BMRN) – Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.
The profile contains critical company information including:

- Business description – A detailed description of the company’s operations and business divisions.
- Corporate strategy – Analyst’s summarization of the company’s business strategy.
- SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
- Company history – Progression of key events associated with the company.
- Major products and services – A list of major products, services and brands of the company.
- Key competitors – A list of key competitors to the company.
- Key employees – A list of the key executives of the company.
- Executive biographies – A brief summary of the executives’ employment history.
- Key operational heads – A list of personnel heading key departments/functions.
- Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
- Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
- Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.

Highlights

BioMarin Pharmaceutical Inc (BioMarin) is a biopharmaceutical company which develops and commercializes innovative pharmaceuticals for treatment of serious diseases and medical conditions, such as Duchenne muscular dystrophy (DMD), phenylketonuria (PKU), achondroplasia, late infantile neuronal ceroid lipofuscinosis (CLN2) and hemophilia A. Its product category consists of multiple clinical and preclinical offerings. The company operates through its manufacturing facilities in Novato, California. It conducts its business operations in the US, Europe, Latin America, the Middle East and Asia-Pacific. BioMarin is headquartered in San Rafael, California, the US.

BioMarin Pharmaceutical Inc Key Recent Developments

Apr 21,2020 BioMarin appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations
Feb 26,2020 BioMarin announces fourth quarter and record full-year 2019 financial results
Feb 03,2020 BioMarin announces CFO succession
Dec 10,2019 Invitae announces program with BioMarin to expand access to genetic testing for Skeletal Dysplasias

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.

Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
- The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.

Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
- Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.

Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
- Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.

Gain key insights into the company for academic or business research.
- Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.

Note: Some sections may be missing if data is unavailable for the company

【レポートの目次】

Table of Contents
Table of Contents
List of Tables
List of Figures
Section 1 – About the Company
BioMarin Pharmaceutical Inc – Key Facts
BioMarin Pharmaceutical Inc – Key Employees
BioMarin Pharmaceutical Inc – Key Employee Biographies
BioMarin Pharmaceutical Inc – Major Products and Services
BioMarin Pharmaceutical Inc – History
BioMarin Pharmaceutical Inc – Company Statement
BioMarin Pharmaceutical Inc – Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries
Joint Venture
Section 2 – Company Analysis
Company Overview
BioMarin Pharmaceutical Inc – Business Description
Product Category: Aldurazyme
Overview
Performance
Product Category: Brineura
Overview
Performance
Product Category: Firdapse
Overview
Performance
Product Category: Kuvan
Overview
Performance
Product Category: Naglazyme
Overview
Performance
Product Category: Palynziq
Overview
Performance
Product Category: Vimizim
Overview
Performance
Geographical Segment: Europe
Performance
Geographical Segment: Latin America
Performance
Geographical Segment: Rest of the World
Performance
Geographical Segment: United States
Performance
BioMarin Pharmaceutical Inc – Corporate Strategy
BioMarin Pharmaceutical Inc – SWOT Analysis
SWOT Analysis – Overview
BioMarin Pharmaceutical Inc – Strengths
BioMarin Pharmaceutical Inc – Weaknesses
BioMarin Pharmaceutical Inc – Opportunities
BioMarin Pharmaceutical Inc – Threats
BioMarin Pharmaceutical Inc – Key Competitors
Section 3 – Company Financial Ratios
Financial Ratios – Capital Market Ratios
Financial Ratios – Annual Ratios
Performance Chart
Financial Performance
Financial Ratios – Interim Ratios
Financial Ratios – Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Recent Deals Summary
Section 5 – Company’s Recent Developments
Apr 21, 2020: BioMarin appoints Global Pharmaceutical Veteran C. Greg Guyer, Ph.D., to Chief Technical Officer, Executive Vice President of Global Manufacturing and Technical Operations
Feb 26, 2020: BioMarin announces fourth quarter and record full-year 2019 financial results
Feb 03, 2020: BioMarin announces CFO succession
Dec 10, 2019: Invitae announces program with BioMarin to expand access to genetic testing for Skeletal Dysplasias
Oct 23, 2019: BioMarin announces third quarter 2019 financial results
Oct 07, 2019: BioMarin promotes Lon Cardon, Ph.D. to Chief Scientific Strategy Officer
Aug 01, 2019: BioMarin announces second quarter 2019 Financial Results
Jul 09, 2019: BioMarin appoints pharmaceutical veteran and former J & J executive, Liz McKee Anderson, to Board of Directors
Apr 25, 2019: BioMarin announces first quarter 2019 financial results
Feb 21, 2019: BioMarin announces full year and fourth quarter 2018 results
Section 6 – Appendix
Methodology
Ratio Definitions
About GlobalData
Contact Us
Disclaimer

List of Tables
BioMarin Pharmaceutical Inc, Key Facts
BioMarin Pharmaceutical Inc, Key Employees
BioMarin Pharmaceutical Inc, Key Employee Biographies
BioMarin Pharmaceutical Inc, Major Products and Services
BioMarin Pharmaceutical Inc, History
BioMarin Pharmaceutical Inc, Subsidiaries
BioMarin Pharmaceutical Inc, Joint Venture
BioMarin Pharmaceutical Inc, Key Competitors
BioMarin Pharmaceutical Inc, Ratios based on current share price
BioMarin Pharmaceutical Inc, Annual Ratios
BioMarin Pharmaceutical Inc, Annual Ratios (Cont...1)
BioMarin Pharmaceutical Inc, Interim Ratios
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Type, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures
BioMarin Pharmaceutical Inc, Performance Chart (2015 - 2019)
BioMarin Pharmaceutical Inc, Ratio Charts
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2014 to YTD 2020
BioMarin Pharmaceutical Inc, Pharmaceuticals & Healthcare, Deals by Type, 2014 to YTD 2020

★海外企業調査レポート[BioMarin Pharmaceutical Inc (BMRN):企業の財務・戦略的SWOT分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nightstar Therapeutics PLC (NITE):製薬・医療:M&Aディール及び事業提携情報
    Summary Nightstar Therapeutics PLC (Nightstar Therapeutics), formerly Nightstar Therapeutics Ltd, is a clinical-stage gene therapy company. The company focus on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases. Its lead product cand …
  • LG Uplus Corp:企業の戦略・SWOT・財務情報
    LG Uplus Corp - Strategy, SWOT and Corporate Finance Report Summary LG Uplus Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate …
  • Sypris Solutions, Inc.:戦略・SWOT・企業財務分析
    Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report Summary Sypris Solutions, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • ISMT Limited:企業の戦略・SWOT・財務情報
    ISMT Limited - Strategy, SWOT and Corporate Finance Report Summary ISMT Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Escalon Medical Corp (ESMC):医療機器:M&Aディール及び事業提携情報
    Summary Escalon Medical Corp (Escalon) is a medical device company with primary focus on ophthalmology. It carries out the development and sale of ophthalmic medical devices. Its major products include A-Scan and B-Scan diagnostic tools, UBM high frequency/high resolution ultrasound devices, pachyme …
  • PDL BioPharma Inc (PDLI)-医療機器分野:企業M&A・提携分析
    Summary PDL BioPharma Inc (PDL) formerly Protein Design Labs, Inc., manages a portfolio of patents and royalty assets that include Queen et al. patents and license agreements with various pharmaceutical and biotechnology companies, and royalty and other acquired assets. It offers financing solutions …
  • Repsol Sinopec Resources UK Ltd:石油・ガス:M&Aディール及び事業提携情報
    Summary Repsol Sinopec Resources UK Ltd (Repsol Sinopec), formerly Talisman Sinopec Energy UK Ltd is an oil and gas company that offers exploration services. The company explores, discovers, and produces oil and gas across the North Sea. It provides operation in floating facilities, offshore platfor …
  • International Zeolite Corp
    International Zeolite Corp - Strategy, SWOT and Corporate Finance Report Summary International Zeolite Corp - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and servi …
  • Tampa Electric Co:電力:M&Aディール及び事業提携情報
    Summary Tampa Electric Company (TEC), a subsidiary of Emera Inc., is an energy utility. It conducts the generation, purchase, transmission, distribution and sale of electricity and the distribution, purchase and sale of natural gas in Florida. The service area for electric operations covers West Cen …
  • Pt Panorama Sentrawisata Tbk
    Pt Panorama Sentrawisata Tbk - Strategy, SWOT and Corporate Finance Report Summary Pt Panorama Sentrawisata Tbk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and s …
  • Murmanskoye Morskoye Parokhodstvo:企業の戦略・SWOT・財務分析
    Murmanskoye Morskoye Parokhodstvo - Strategy, SWOT and Corporate Finance Report Summary Murmanskoye Morskoye Parokhodstvo - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • NHPC Ltd (NHPC)-エネルギー分野:企業M&A・提携分析
    Summary NHPC Ltd. (NHPC), a Government of India Enterprise, is an energy utility that plans, promotes, and organizes integrated development of hydro power plants. The company generates electricity primarily from hydro sources and also harnesses conventional and non-conventional sources such as therm …
  • Cemex SAB de CV (CEMEXCPO):企業の財務・戦略的SWOT分析
    Cemex SAB de CV (CEMEXCPO) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesse …
  • Median Technologies SA (ALMDT):企業の財務・戦略的SWOT分析
    Summary Median Technologies SA (Median) is a medical technology company that develops and markets medical imaging solutions. The company offers clinical trials, imaging services for CT, scientific consulting, image and clinical data management, image data processing and site support, managed service …
  • TreeHouse Foods Inc:企業の戦略・SWOT・財務分析
    TreeHouse Foods Inc - Strategy, SWOT and Corporate Finance Report Summary TreeHouse Foods Inc - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings a …
  • Cytodyn Inc (CYDY):製薬・医療:M&Aディール及び事業提携情報
    Summary Cytodyn Inc (Cytodyn) is a clinical-stage biotechnology company focused on the clinical development and potential commercialization of humanized monoclonal antibodies t for the treatment of Human Immunodeficiency Virus (HIV) infections. The company's products pipeline include PRO 140, Cytofe …
  • Electric Power Development Co Ltd:発電所・企業SWOT分析
    Electric Power Development Co Ltd - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on …
  • Noble Mineral Exploration Inc (NOB):企業の財務・戦略的SWOT分析
    Summary Noble Mineral Exploration Inc (Noble Mineral) is a mining and mineral exploration and development company that offers mineral resources. The company offers acquisition, exploration mining, production, and development of gold, nickel, copper, zinc, uranium, and mineral resources deposit prope …
  • Sacmi Imola S.C. :企業の戦略・SWOT・財務情報
    Sacmi Imola S.C. - Strategy, SWOT and Corporate Finance Report Summary Sacmi Imola S.C. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and cor …
  • Ardian Holding SAS:企業の戦略的SWOT分析
    Ardian Holding SAS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and ser …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆